Hybridoma Generation for Therapeutic Antibody Drug Discovery and Applications

Therapeutic antibody drugs have recently experienced explosive growth. Within oncology research alone, 14 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015. Additionally, more than 300 therapeutic antibody drugs are in ongoing clinical trials. Driven by the increase in biomarker discovery, more and more therapeutic antibody drugs are set to enter the market with increased competition. Therefore, to maximize the success of therapeutic antibody drug development, it is essential to thoroughly vet antibody drug candidates at every step of the process. This webinar will review the current platforms for generating antibodies and discuss the screening and characterization technologies required for rational selection of lead therapeutic antibody drug candidates. We will examine key case studies demonstrating appropriate use of cutting edge high throughput screening platforms to guide hybridoma clone selection. Ultimately, attendees will understand how these approaches integrate with both upstream and downstream therapeutic antibody drug discovery methodologies.

Speaker-related Webinars

Identify the optimal protein purification strategy for your recombinant protein production

Are you challenged with obtaining sufficient amount of high purity proteins for your applications? Almost unavoidably, every protein purification step results in some degree of protein loss.

Learn More

Recombinant protein expression & purification

Are you struggling with the amount and/or purity of your recombinant protein? Attend this online seminar for solutions to the challenges in recombinant protein expression & purification.

Learn More

Accelerating Lead Identification Through Paramagnetic Bead Purification Technology

High throughput purification is a critical step in antibody engineering and lead identification. Paramagnetic bead technology allows a single step purification of targets by simply adding the beads directly

Learn More

Efficient stable cell pool/cell line development for large-scale antibody and protein production

Interested in rapid and efficient stable cell pool/cell line development for large-scale production of your recombinant antibodies and proteins? If so, this webinar may be for you.

Learn More

Chaperone co expression strategies for recombinant soluble protein production in E. Coli

Recombinant protein expression in E. coli often results in the formation of insoluble aggregates called inclusion bodies.

Learn More